Apr 22 |
S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings
|
Apr 19 |
Hepion ends Phase 2 study for NASH drug due to cash restraints
|
Apr 19 |
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
|
Mar 6 |
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
|
Feb 16 |
Hepion announces exercise of warrants for about $2M gross proceeds
|
Feb 16 |
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
|
Jan 3 |
Hepion Pharmaceuticals to Present at NASH-TAG 2024
|
Dec 7 |
Hepion Pharma announces restructuring plan, sees $400–800 thousand charge for 4Q
|
Dec 7 |
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
|
Nov 28 |
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
|